About: Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne. In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform. It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products. The company is based in Cambridge, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $2.04 (-0.97%)
HIND NASDAQ Vyome Holdings, Inc.
Vyome Holdings, Inc. share price
HIND price activity
Last Price
$2.040
Change (24hr)
-0.02 USD (-0.97%)
Volume
11.31K
Volume (4w avg)
-
Open
$2.02
Day Range
$1.98 - $2.06
Previous Close
$2.06
Last Trade
07 Oct, 8:00 pm GMT+0
Delayed
07 Oct, 8:00 pm GMT+0
HIND price performance
Delayed
07 Oct, 8:00 pm GMT+0
HIND Market Signals